(NASDAQ: VRTX) Vertex Pharmaceuticals's forecast annual revenue growth rate of 7.34% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 99.6%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.68%.
Vertex Pharmaceuticals's revenue in 2025 is $11,723,300,000.On average, 35 Wall Street analysts forecast VRTX's revenue for 2025 to be $3,103,742,459,623, with the lowest VRTX revenue forecast at $2,958,869,007,122, and the highest VRTX revenue forecast at $3,254,705,164,068. On average, 33 Wall Street analysts forecast VRTX's revenue for 2026 to be $3,374,967,889,962, with the lowest VRTX revenue forecast at $2,997,180,550,603, and the highest VRTX revenue forecast at $3,764,172,576,716.
In 2027, VRTX is forecast to generate $3,687,295,770,923 in revenue, with the lowest revenue forecast at $2,943,392,158,431 and the highest revenue forecast at $4,261,968,923,138.